Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome.
Tassone P, Tagliaferri P, Cucinotto I, Lavecchia AM, Leone F, Pietragalla A, Salvino A, Barbieri V, Venuta S. Tassone P, et al. Among authors: salvino a. Ann Oncol. 2007 May;18(5):959-60. doi: 10.1093/annonc/mdm113. Ann Oncol. 2007. PMID: 17488733 Free article. No abstract available.
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A. Mignogna C, et al. Among authors: salvino a. J Ovarian Res. 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7. J Ovarian Res. 2016. PMID: 27209210 Free PMC article.
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics.
Staropoli N, Arbitrio M, Salvino A, Scionti F, Ciliberto D, Ingargiola R, Labanca C, Agapito G, Iuliano E, Barbieri V, Cucè M, Zuccalà V, Cannataro M, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: salvino a. Biomedicines. 2022 May 23;10(5):1210. doi: 10.3390/biomedicines10051210. Biomedicines. 2022. PMID: 35625946 Free PMC article.
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: salvino a. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: salvino a. Crit Rev Oncol Hematol. 2024 Jan;193:104229. doi: 10.1016/j.critrevonc.2023.104229. Epub 2023 Dec 7. Crit Rev Oncol Hematol. 2024. PMID: 38065404 Free article. Review.
16 results